prescribing precision and management for a wide range of mental health conditions.

PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*.

PREDICTIX PRODUCTS

- PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions.

- PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI.

PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space.

PREDICTIX is commercially available in Europe. Learn more at predictix.ai.

*Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration.

Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.